Beta-Endorphin 1–31 Biotransformation and cAMP Modulation in Inflammation

A large body of evidence now exists for the immune cell expression, production, and the release of beta-endorphin (BE 1–31) within inflamed tissue. The inflammatory milieu is characterised by increased acidity, temperature and metabolic activity. Within these harsh conditions BE 1–31 is even more susceptible to increased enzymatic degradation over that of plasma or other non-injured tissue. To elucidate the biotransformation pathways of BE 1–31 and provide an insight to the impact of inflamed tissue environments, BE 1–31 and three of its major N-terminal fragments (BE 1–11, BE 1–13 and BE 1–17) were incubated in inflamed tissue homogenates at pH 5.5 for 2 hrs. In addition, the potency of BE 1–31 and five main N – terminal fragments (BE 1–9, BE 1–11, BE 1–13, BE 1–17, BE 1–20) was assessed at mu-opioid receptors (MOR), delta-opioid receptors (DOR), and kappa-opioid receptors (KOR). Opioid receptor potency was investigated by examining the modulation of forskolin induced cAMP accumulation. The majority of the N-terminal fragment of BE 1–31 had similar efficacy to BE 1–31 at MOR. The shortest of the major N-terminal fragments (BE 1–9), had partial agonist activity at MOR but possessed the highest potency of all tested peptides at DOR. There was limited effect for BE 1–31 and the biotransformed peptides at KOR. Major N-terminal fragments produced within inflamed tissue have increased presence within inflamed tissue over that of the parent molecule BE 1–31 and may therefore contribute to BE 1–31 efficacy within disease states that involve inflammation.

[1]  B. Roques,et al.  Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  P. N. Shaw,et al.  Study of beta endorphin metabolism in inflamed tissue, serum and trypsin solution by liquid chromatography–tandem mass spectrometric analysis , 2012, Analytical and Bioanalytical Chemistry.

[3]  B. Hammock,et al.  Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP , 2011, Proceedings of the National Academy of Sciences.

[4]  T. Ng,et al.  beta-Endorphin: isolation, amino acid sequence and synthesis of the hormone from horse pituitary glands. , 2009, International journal of peptide and protein research.

[5]  G. Yadid,et al.  β-Endorphin and drug-induced reward and reinforcement , 2008, Progress in Neurobiology.

[6]  B. Chait,et al.  Extracellular Biotransformation of β‐Endorphin in Rat Striatum and Cerebrospinal Fluid , 2008, Journal of neuroendocrinology.

[7]  B. Tamba,et al.  Variation in the analgesic activity of opioid peptide fragments in correlation with the amino acidic sequence , 2007 .

[8]  B. Roques,et al.  Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs , 2007, Expert opinion on therapeutic targets.

[9]  I. Vetter,et al.  The μ opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway , 2006, Molecular pain.

[10]  J. Fichna,et al.  Opioid peptides in cancer , 2004, Cancer and Metastasis Reviews.

[11]  C. Stein,et al.  Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue , 2004, The European journal of neuroscience.

[12]  K. Tan-No,et al.  Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. , 2003, Biochemical pharmacology.

[13]  T. Rogers,et al.  Interactions between opioid and chemokine receptors: heterologous desensitization. , 2002, Cytokine & growth factor reviews.

[14]  P. Cabot,et al.  Methionine-enkephalin-and Dynorphin A-release from immune cells and control of inflammatory pain , 2001, Pain.

[15]  H. Rittner,et al.  Opioid Peptide–expressing Leukocytes: Identification, Recruitment, and Simultaneously Increasing Inhibition of Inflammatory Pain , 2001, Anesthesiology.

[16]  Jean-François Trottier,et al.  Role of endogenous opioid system in the regulation of the stress response , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  R. Ji,et al.  β-Endorphin-containing memory-cells and μ-opioid receptors undergo transport to peripheral inflamed tissue , 2001, Journal of Neuroimmunology.

[18]  P. Lobel,et al.  The Human CLN2 Protein/Tripeptidyl-Peptidase I Is a Serine Protease That Autoactivates at Acidic pH* , 2001, The Journal of Biological Chemistry.

[19]  G. Ekström,et al.  Tissue and intracellular pH in normal periarticular soft tissue and during different phases of antigen induced arthritis in the rat. , 1999, The Journal of rheumatology.

[20]  L. Hersh,et al.  Anti-CD3 activation of human CD4+ T cells increases expression of the intracellular β-endorphin endopeptidase (IDE/γ-EpGE) , 1998, Journal of Neuroimmunology.

[21]  J. Silberring,et al.  Metabolism of β-endorphin in plasma studied by liquid chromatography–electrospray ionization mass spectrometry , 1998, Regulatory Peptides.

[22]  Xuegong Zhu,et al.  β-Endorphin-Containing Proteins in the Human Pituitary , 1997, Peptides.

[23]  J. Loeffler,et al.  Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. , 1997, The Journal of clinical investigation.

[24]  P. Keck,et al.  Cerebrospinal fluid and plasma β-endorphin in combat veterans with post-traumatic stress disorder , 1997, Psychoneuroendocrinology.

[25]  B. Roques,et al.  Nociceptin/Orphanin FQ Metabolism: Role of Aminopeptidase and Endopeptidase 24.15 , 1997, Journal of neurochemistry.

[26]  L. Hersh,et al.  Identification of γ-Endorphin-Generating Enzyme as Insulin-Degrading Enzyme† , 1996 .

[27]  P. Reeh,et al.  Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia? , 1996, Neuroscience Letters.

[28]  L. Hersh,et al.  A secreted peptidase involved in T cell β-endorphin metabolism , 1996 .

[29]  B. Mehlis,et al.  Liquid chromatographic-mass spectrometric studies on the enzymatic degradation of beta-endorphin by endothelial cells. , 1995, Journal of chromatography. A.

[30]  C. Stein.  The control of pain in peripheral tissue by opioids. , 1995, The New England journal of medicine.

[31]  C. Stein,et al.  Peripheral Mechanisms of Opioid Analgesia , 1993, Anesthesia and analgesia.

[32]  W. Sadee,et al.  Regulation of Cyclic AMP by the μ‐Opioid Receptor in Human Neuroblastoma SH‐SY5Y Cells , 1990, Journal of neurochemistry.

[33]  P. Sacerdote,et al.  Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: Preliminary data , 1990, Psychiatry Research.

[34]  M. Karol.  Mean residence time and the meaning of AUMC/AUC. , 1990, Biopharmaceutics & drug disposition.

[35]  Peter Veng-Pedersen,et al.  Mean Time Parameters in Pharmacokinetics , 1989 .

[36]  J. Burbach,et al.  Properties of a Leu‐Phe‐Cleaving Endopeptidase Activity Putatively Involved in β‐Endorphin Metabolism in Rat Brain , 1989, Journal of neurochemistry.

[37]  V. Hruby,et al.  Opioid receptor selectivity of beta-endorphin in vitro and in vivo: mu, delta and epsilon receptors. , 1988, The Journal of pharmacology and experimental therapeutics.

[38]  D. Dewied,et al.  Non-opiate effects of neuropeptides derived from beta-endorphin. , 1987 .

[39]  J. Morley,et al.  Enhancement of human lymphocyte natural killing function by non-opioid fragments of beta-endorphin. , 1987, Life sciences.

[40]  J. van Ree,et al.  Beta-endorphin-(10-16) antagonizes behavioral responses elicited by melatonin following injection into the nucleus accumbens of rats. , 1985, Life sciences.

[41]  J. Burbach,et al.  Proteolytic conversion of beta-endorphin by brain synaptic membranes. Characterization of generated beta-endorphin fragments and proposed metabolic pathway. , 1981, The Journal of biological chemistry.

[42]  J. Mcdonald,et al.  Dipeptidyl peptidase II of bovine dental pulp. Initial demonstration and characterization as a fibroblastic, lysosomal peptidase of the serine class active on collagen-related peptides. , 1980, Biochimica et biophysica acta.

[43]  R. Houghten,et al.  beta-Endorphin: stability, clearance behavior, and entry into the central nervous system after intravenous injection of the tritiated peptide in rats and rabbits. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Burbach,et al.  β-Endorphin biotransformation in brain: Formation of γ-endorphin by a synaptosomal plasma membrane associated endopeptidase distinct from cathepsin D , 1980 .

[45]  Choh Hao Li,et al.  β-Endorphin: Analgesic and hormonal effects in humans , 1979 .

[46]  R. Ji,et al.  beta-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. , 2001, Journal of neuroimmunology.

[47]  K. Chaturvedi,et al.  Structure and regulation of opioid receptors. , 2000, Biopolymers.

[48]  D. Desiderio,et al.  Beta-endorphin-containing proteins in the human pituitary. , 1997, Peptides.

[49]  P Veng-Pedersen,et al.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II). , 1989, Clinical pharmacokinetics.

[50]  J. van Ree,et al.  Non-opiate effects of neuropeptides derived from beta-endorphin. , 1987, Polish journal of pharmacology and pharmacy.